Glucose-6-phosphate dehydrogenase deficiency screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(8 intermediate revisions by 2 users not shown)
Line 4: Line 4:
{{CMG}}; {{AE}} {{MA}}
{{CMG}}; {{AE}} {{MA}}
==Overview==
==Overview==
G6PD defeciency screening in [[neonates]] is done routinly in some regions with high [[incidence]].


There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
==Screening==
==Screening==
G6PD defeciency screening in neonates is done routinly in some regions with high incidence. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref>
*G6PD defeciency screening in neonates is done routinly in some regions with high [[incidence]]. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref>
 
*Screening test is quantitative laboratory assay for G6PD enzyme activity.
Screening is done before giving oxidant medication to high risk patients.  
*Screening is done before giving [[oxidant]] medication to high risk patients.  
 
*There is insufficient evidence to recommend routine screening for G6PD deficiency.
There is insufficient evidence to recommend routine screening for [disease/malignancy].
 
According to the [guideline name], screening for [disease name] is not recommended.
 
OR
 
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
*[Condition 1]
*[Condition 2]
*[Condition 3]


==References==
==References==
Line 36: Line 18:
{{WS}}
{{WS}}
[[Category: (name of the system)]]
[[Category: (name of the system)]]
{{Glucose-6-phosphate dehydrogenase deficiency}}
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com]
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
==Overview==
==References==
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Mature chapter]]
[[Need content]]

Latest revision as of 18:41, 25 October 2018

Glucose-6-phosphate dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucose-6-phosphate dehydrogenase deficiency screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucose-6-phosphate dehydrogenase deficiency screening

CDC on Glucose-6-phosphate dehydrogenase deficiency screening

Glucose-6-phosphate dehydrogenase deficiency screening in the news

Blogs on Glucose-6-phosphate dehydrogenase deficiency screening

Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency

Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]

Overview

G6PD defeciency screening in neonates is done routinly in some regions with high incidence.

Screening

  • G6PD defeciency screening in neonates is done routinly in some regions with high incidence. [1]
  • Screening test is quantitative laboratory assay for G6PD enzyme activity.
  • Screening is done before giving oxidant medication to high risk patients.
  • There is insufficient evidence to recommend routine screening for G6PD deficiency.

References

  1. Kaplan M, Hammerman C (February 2009). "The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective". J Perinatol. 29 Suppl 1: S46–52. doi:10.1038/jp.2008.216. PMID 19177059.

Template:WH Template:WS